When is aacr 2011

Kornbluth, and Nickolas Papadopoulos Program. Gray, and William R. Sellers Program. Rosen Program. Kittles, and Miguel A. Villalona-Calero Program Abstracts. Jain, William G. Kaelin, Jr. Lane, and Helen M. Piwnica-Worms Program Abstracts. Eaves, and Geoffrey M.

Wahl Program. Lowe, Curtis C. Harris, and Scott L. Kimple, M. Chung, Ph. Mullighan, M. Jude Children's Research Hospital Exome sequencing of hypodiploid acute lymphoblastic leukemia The whole idea of finding out what molecules are available to be drugged or treated is very exciting; there was a whole session on this.

Now Nigel Brooks gave a presentation, what was that all about and which cancers and what came out of it? There had been a first generation of FGFR inhibitors several years ago and those turned out to be not very well tolerated in the clinic and the culprit was thought to be FGFR4. So this new generation of drugs now has eliminated FGFR4 activity, focussed on the actual drivers in cancer, FGFR1, 2 and 3, and then the hope with these new molecules is when they enter phase I they will be tolerated and yet also be able to be targeted to the patients who have driver mutations.

And the data you heard was on gastric and hematologic malignancies, what came up? The preclinical models, for instance the evaluated gastric cancer patient models with FGFR2 amplifications , and those indeed showed cell death when treated with these inhibitors.

So we think these are very promising and look forward to new data as the phase I trials progress. So there are some dual inhibitors in the clinic like lapatinib which has approval in breast cancer and the goal of this project was to say, OK, can we reduce any of the side effects and increase the tolerability and how will we progress that in the clinic?

If we can get more drug on will we be more effective? There are some hints of efficacy, so there was a bit of phase I data presented in some HER2 positive patients and there were indeed some PRs. Wahl Abstracts Free Webcasts. Program Chairperson: Sara A. AACR Foundation.

AACR's Impact. About Cancer. Get Involved. Innovators in Discovery. Patient Advocacy. Progress Against Cancer. Survivor Journeys.